Diabetes Monitoring: Human out of the loop

Speak to any one of the world’s 415 million diabetic patients and they will tell you what a burden the constant level of monitoring and treatment delivery of the serious condition can be. Despite the advances in monitoring and delivery technologies, the burden of continuously tracking and adjusting your treatment is greater than you might think. So, what if you are able to take this challenge away from patients?

In this first episode of Invent:Health Season 2, Matt Parker speaks to Chris Dawson, Head of Biosensing at TTP, and Dr. Andrew Chapman, CEO, and Co-Founder of Carbometrics, to explore how patients can be taken out of this monitoring-delivery loop and what technologies are out there that can automate the process entirely.

This Week’s Guests
Chris Dawson – Dr. Chris Dawson is a mechanical engineer who leads the biosensing team at TTP. The team works with clients to leverage advances in biosensing technology to develop products that support patients in managing and treating a wide range of diseases. They develop sensing solutions from short-term minimally invasive to long-term fully implantable, all with challenging requirements for biocompatibility, hermeticity, form-factor, wireless power & comms, and integrate a broad range of sensing modalities from electrical and electrochemical, through to ultrasonic and optical.

Andrew Chapman – Dr. Andrew Chapman is a scientist and entrepreneur who for over a decade, has designed and led interdisciplinary commercial and academic programs across a whole range of different scientific disciplines. Andrew is currently the CEO and co-founder of Carbometrics, a company whose revolutionary biomimetic glucose binding molecules have made them one of the most exciting companies working in this space.